Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Diabetic Gastroparesis Pipeline Review H1 2019: Therapeutic Assessment of 8 Companies & 10 Drug Profiles - ResearchAndMarkets.com

March 25, 2019

DUBLIN--(BUSINESS WIRE)--Mar 25, 2019--The “Diabetic Gastroparesis - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Diabetic Gastroparesis - Pipeline Review, H1 2019, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

This latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Key Topics Covered:

Diabetic Gastroparesis - Overview

Diabetic Gastroparesis - Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Diabetic Gastroparesis - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Diabetic Gastroparesis - Companies Involved in Therapeutics Development

  • AlfaSigma SpA
  • Allergan Plc
  • Censa Pharmaceuticals Inc
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Vanda Pharmaceuticals Inc

Diabetic Gastroparesis - Drug Profiles

  • CNSA-001 - Drug Profile
  • ETX-101 - Drug Profile
  • ETX-301 - Drug Profile
  • metoclopramide - Drug Profile
  • prucalopride succinate - Drug Profile
  • relamorelin - Drug Profile
  • renzapride - Drug Profile
  • TAK-906 - Drug Profile
  • tradipitant - Drug Profile
  • velusetrag - Drug Profile

Featured News & Press Releases

Jan 07, 2019: Evoke Pharma signs commercial and financial agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners

Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis

Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018

Aug 16, 2018: Evoke Pharma’s Gimoti NDA Accepted for FDA Review

Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for Gimoti

May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis

May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico

Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti

Feb 15, 2018: Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti

Oct 27, 2017: Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti

Oct 23, 2017: Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti

Oct 04, 2017: Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

Sep 12, 2017: Evoke Pharma Completes Dosing for Gimoti Comparative Exposure Pharmacokinetic Study

Sep 05, 2017: Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Aug 14, 2017: Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/63h3j3/diabetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005566/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs ,Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/25/2019 11:40 AM/DISC: 03/25/2019 11:40 AM